Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.
Paragraf produces graphene electronic devices using contamination-free technology to deliver commercial-quality products. The company aims to significantly transform the electronics industry by developing high-purity graphene products that enhance technological performance. Paragraf is committed to driving material advancements in electronics through its innovative approach.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.
BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013.
Sagence AI is a semiconductor company developing products in the neural computing segment. They enable server-class networks to be deployed with extremely low latency in cost-effective edge devices. Its unique technology performs data-center-grade AI workloads at orders of magnitude lower power.
Phase Four is a provider of electric propulsion (EP) for small satellites. The company was founded in 2015 to accelerate the advancement of its core differentiator, the Radio Frequency Thruster (RFT). The hallmark of Phase Four’s RFT is simplicity. Because the RFT omits a hollow cathode and high voltage electronics, three key improvements are realized: 1) a 10x materials cost savings versus legacy EP systems, 2) a significant decrease in the size of power electronics, and 3) propellant agnosticism. In a first for EP, the Phase Four RF thruster accomplishes this while achieving performance in the same thrust, specific impulse (Isp), and efficiency class as legacy plasma propulsion solutions.
Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.
Founded in 2014, Zeotap’s mission is to help brands monetise customer data in a privacy-first Europe. Today, Zeotap owns three data solutions. Zeotap CDP is the easy, secure and impactful Customer Data Platform that empowers brands to integrate, unify, segment and orchestrate customer data. Zeotap Data delivers quality targeting at scale by enabling the activation of 2,500 tried-and-tested Champion Segments across 100+ programmatic and social platforms. Zeotap ID+ is a universal marketing ID initiative that paves the way for addressability in the cookieless future.
ABL Space Systems focuses on developing and launching low-cost, reliable rockets designed for small satellite payloads. Their primary launch vehicle is the RS1 rocket, designed to deliver small satellites to orbit cheaply. The RS1 can carry payloads of up to 1,350 kilograms to the Low Earth Orbit (LEO). The company also develops the GS0 ground system, which supports rapid deployment and integration of launch operations at various locations. ABL is headquartered in El Segundo, California, with 30,000 square feet of research, development, and production facilities. ABL is a privately owned corporation backed by a premier group of private equity investors
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
DUST — the Diamond Unclonable Security Tag — is a proprietary technology which utilizes nanodiamonds to create an unclonable identity layer on any object. An optical scanner and cloud-based infrastructure provides an interface to the object identity and provenance. DUST ensures that trusted data and verifiable products are used and traced across their full lifecycle.
PlanetIQ utilizes commercial satellite constellations to provide weather data for on-the-ground decision-making. The costs of natural disasters are soaring as extreme weather increases and the population expands, putting more and more lives and property at risk. Meanwhile, smarter and more powerful weather and climate models are hungry for the data they need to produce more precise forecasts on time scales ranging from hourly to decadal. Yet the traditional model for government-funded satellite programs has not kept up with today’s technology and the rising demand for data. Aging spacecraft, budget constraints, and schedule delays threaten critical gaps in data crucial to monitoring and predicting day-to-day weather, hurricanes and winter storms, floods and drought, space weather, and climate change.
Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.
BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013.
DUST — the Diamond Unclonable Security Tag — is a proprietary technology which utilizes nanodiamonds to create an unclonable identity layer on any object. An optical scanner and cloud-based infrastructure provides an interface to the object identity and provenance. DUST ensures that trusted data and verifiable products are used and traced across their full lifecycle.
Svelte Medical Systems (Svelte) is a privately held company focused on delivering novel products in the $5 billion coronary stent market. Its mission is to address key clinical issues in the stent market by improving stent deliverability, reducing cost, and dramatically improving the safety of the device compared to current market products. Svelte has developed the lowest profile and most deliverable balloon-expandable stent in the market, along with technology to create a non-thrombogenic, non-inflammatory Drug-Eluting Stent (DES). Svelte was started by Robert Fischell, David Fischell, and Tim Fischell in 2007.
ISORG is the pioneer company in organic and printed electronics for large area photo-detectors and image sensors.ISORG offers complete services from proof-of-concept to mass production for innovative opto-electronics systems (hardware and software).
Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.
Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.
Our view is a world where nothing is missed and one pair does it all. Because there’s more to see than ever before, and you deserve to see the bigger picture without edges or limitations. Our story starts with Jelle De Smet and Paul Marchal, two pioneers who with combined experience in electronics and nanotechnology invented the Autofocal lens. They saw a better way, where ageing eyesight is no longer a burden and progressive lenses were a prequel. And so Morrow was founded in 2016 — followed by years of research, development and meticulous fine-tuning. We now launch our flagship Autofocal Eyewear that combines Active Liquid Crystal and a two-layer corrective lens to transform your vision — both near and far — at the touch of a button. In our eyes, independence is a state of mind. It’s the unshackled freedom to do what you want and on your own terms, whilst always improving. Discover why there is always mor’ to see.
ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.
Escalier Biosciences B.V. operates in the healthcare industry focusing on biotechnology business. The company was incorporated in 2016 and is based in Nijmegen, the Netherlands.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Founded in 2014, Zeotap’s mission is to help brands monetise customer data in a privacy-first Europe. Today, Zeotap owns three data solutions. Zeotap CDP is the easy, secure and impactful Customer Data Platform that empowers brands to integrate, unify, segment and orchestrate customer data. Zeotap Data delivers quality targeting at scale by enabling the activation of 2,500 tried-and-tested Champion Segments across 100+ programmatic and social platforms. Zeotap ID+ is a universal marketing ID initiative that paves the way for addressability in the cookieless future.
Caringo Inc. is an innovative software provider focused on delivering the most advanced object-based technology for accessing, storing and distributing unstructured or file-based data. Its flagship product, CAStor, enables private cloud storage that dramatically improves the scope and economics of storing content by enabling customers to implement robust storage clusters without being locked into proprietary hardware. Founded on the operating principle that things should be made as simple as possible and a customer-first focus, Caringo makes content and file storage affordable, scalable, fast and easy.
BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013.
VUV Analytics was incorporated in Austin, TX in December 2009, as a spin-off from a semiconductor equipment company. The five founders bring with them critical and unique know-how related to the hardware, software, analysis, intellectual property, and marketing associated with VUV technologies. The team's past success in pioneering VUV reflectometry for use in the semiconductor metrology field yielded several key market wins and an extensive IP portfolio, including 32 issued patents and 12 pending patents.
Kateeva (formerly TJet Technologies) is driving new advances in OLED production technology. Our inkjet printing manufacturing equipment solution enables flexible and large-size OLEDs to be produced over large areas and in high volume – with longer lifetimes, higher yields and lower production costs. It’s the first economically viable and production-worthy technique to use printing for low-cost mass-production of OLEDs – which means big innovation for the display industry. And for consumer electronics fans, it means those spectacular 55” OLED TVs will soon be within reach, and cool paper-thin, ultra-light wearable computing products will dazzle with extra smarts and smaller form factors. At our LinkedIn home, we’ll keep you up-to-the-minute on our tech milestones and latest moves. And since we’re huge fans on all-things OLED, we’ll occasionally add other cool technology stuff that inspires us to out-invent – even ourselves!
Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.
Private Equity Round in 2016
Svelte Medical Systems (Svelte) is a privately held company focused on delivering novel products in the $5 billion coronary stent market. Its mission is to address key clinical issues in the stent market by improving stent deliverability, reducing cost, and dramatically improving the safety of the device compared to current market products. Svelte has developed the lowest profile and most deliverable balloon-expandable stent in the market, along with technology to create a non-thrombogenic, non-inflammatory Drug-Eluting Stent (DES). Svelte was started by Robert Fischell, David Fischell, and Tim Fischell in 2007.
Akarna Therapeutics is a biopharmaceutical company with offices in San Diego and Cambridge (UK) that is developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Our lead program is a non-bile acid FXR agonist that is potentially a best-in-class therapeutic for the treatment of nonalcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies. Akarna’s lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies with first-in-human studies planned for early 2017.
Ovizio develops digital holographic interferometric microscopy products. It builds 4D microscopic imaging devices and software based on digital holographic microscopy.
Fuzzy Logix in-database analytics solutions you’re not bound by the constraints of traditional analytics. By eliminating the need for data extraction, middle-tier analytics servers and redundant data storage, our products allow you to process your analytics within the database and make massive time, cost and resource savings.
EXTEN provides high-performance storage software to hyperscale data centers. EXTEN’s agile, reliable, and scalable solution is well suited for the most demanding high-performance, low-latency workloads where needs are highly variable and unpredictable including e-commerce, real-time analytics, and video processing, financial and trading applications, transaction processing, and buffering workloads with large-scale file systems. Founded in 2012, EXTEN Technologies is a pioneer in ultra-high-performance NVMe over Fabrics storage software applications. EXTEN is venture capital funded and is based in Austin, Texas.
Vorago Technologies is afabless semiconductor company. It is formerly known as Silicon Space Technology. Vorago is a provider of radiation-hardened and extreme temperature-hardened IC components for the Hi-rel marketplace. Vorago designs and develops high-density SRAMs and logic ICs using its patented HARDSIL technology to simultaneously provide superior radiation and temperature endurance performance. Vorago also provides custom ASIC design services using its hardened Metal Programmable System On Chip (MPSoC) platform capability. Vorago's patented, innovative technology, HARDSIL, has been proven in multiple CMOS process generations at multiple fabs to harden integrated circuits without redesign and is scalable to any generation node. Once modified by HARDSIL, the commercial process flow can be used to manufacture significantly more robust CMOS circuits for highly reliable operation in extreme environments. This capability dramatically enhances the hardness and reliability of high-density ICs provides a disruptive alternative to current hi-rel approaches utilizing up screened COTS, redundant systems, or exotic packaging. It was founded in 2004 and based in Austin, Texas.
Ralexar Therapeutics company is developing topical and systemic therapies based on the Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis. Alexar changes its name to Ralexar Therapeutics. The company was founded in 2013 and is based in Malvern, Pennsylvania.
PerceptiMed’s groundbreaking VeriFill™ technology reduces the margin of human error in prescription pill dispensing within retail pharmacies, long-term care facilities and hospitals. Its IdentRx™suite of medication verification and dispensing products are fast, accurate and cost-effective -- providing 100% verification of drug, dosage and manufacturer for every pill, every time.
For businesses moving to the cloud, Vaultive’s encryption in use technology mitigates risk by empowering companies with control and ownership of their data wherever it resides. Vaultive’s customers hold the encryption keys, letting them retain the freedom to use cloud applications professionals rely on, while ensuring the governance and security that business demands.
Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, now one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.
Kateeva (formerly TJet Technologies) is driving new advances in OLED production technology. Our inkjet printing manufacturing equipment solution enables flexible and large-size OLEDs to be produced over large areas and in high volume – with longer lifetimes, higher yields and lower production costs. It’s the first economically viable and production-worthy technique to use printing for low-cost mass-production of OLEDs – which means big innovation for the display industry. And for consumer electronics fans, it means those spectacular 55” OLED TVs will soon be within reach, and cool paper-thin, ultra-light wearable computing products will dazzle with extra smarts and smaller form factors. At our LinkedIn home, we’ll keep you up-to-the-minute on our tech milestones and latest moves. And since we’re huge fans on all-things OLED, we’ll occasionally add other cool technology stuff that inspires us to out-invent – even ourselves!
Svelte Medical Systems (Svelte) is a privately held company focused on delivering novel products in the $5 billion coronary stent market. Its mission is to address key clinical issues in the stent market by improving stent deliverability, reducing cost, and dramatically improving the safety of the device compared to current market products. Svelte has developed the lowest profile and most deliverable balloon-expandable stent in the market, along with technology to create a non-thrombogenic, non-inflammatory Drug-Eluting Stent (DES). Svelte was started by Robert Fischell, David Fischell, and Tim Fischell in 2007.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.
Ario Pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease.
BrightVolt is an innovative manufacturer of solid-state thin & flexible lithium polymer batteries and power-efficient thin & flexible microelectronics for IoT clients. It specializes in the fields of battery, electronics, and manufacturing. BrightVolt got recapitalization in November 13, 2013.
Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.
Resolve Therapeutics is a private biotechnology company that is dedicated to the goal of improving the lives of patients suffering from lupus. They are focused on the advancement their exciting, novel biologic compound, RSLV-125 from preclinical research through a phase IIa clinical trial. The company is based on the pioneering discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter in their laboratories at the University of Washington School of Medicine.
Achronix is a privately held fabless corporation based in Santa Clara, California. Achronix is the only company to offer high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Called Speedster®22i, Achronix’s FPGAs are built on Intel’s advanced 22nm process featuring 3-D Tri-Gate transistors and are the first FPGAs to include fully integrated hard IP protocol functions targeted for communications applications. Achronix also offers the Achronix CAD environment (ACE), an easy-to-use, mature, robust design-tool suite for our customers. ACE includes integrated support for industry-standard synthesis tools Synplify Pro and Precision Synthesis, from Synopsys and Mentor Graphics, respectively. Target markets for Achronix FPGAs include: Networking Optical/telecom High-performance computing Test and measurement Military and security Achronix Semiconductor Corporation was founded in 2004 with sales offices in the United States, Europe and China. It has research and development facilities in Santa Clara, California and Bangalore, India.
Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received nondilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.
For businesses moving to the cloud, Vaultive’s encryption in use technology mitigates risk by empowering companies with control and ownership of their data wherever it resides. Vaultive’s customers hold the encryption keys, letting them retain the freedom to use cloud applications professionals rely on, while ensuring the governance and security that business demands.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
Oxyrane UK Limited, a biopharmaceutical company, develops novel and biosuperior enzyme replacement therapies for the treatment of lysosomal storage diseases. It provides human lysosomal enzymes that enable clinically effective enzyme uptake and localization using its glycoengineered yeast platform. The company was founded in 2006 and is based in Manchester, United Kingdom. It has locations in Gent, Belgium; and Burlington, Massachusetts.
Resolve Therapeutics is a private biotechnology company that is dedicated to the goal of improving the lives of patients suffering from lupus. They are focused on the advancement their exciting, novel biologic compound, RSLV-125 from preclinical research through a phase IIa clinical trial. The company is based on the pioneering discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter in their laboratories at the University of Washington School of Medicine.
Lightwire’s mission is to deliver efficient integration of optical and electrical solutions which will power the next generation of high speed interconnects using CMOS photonics technology.
Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform. Celleration’s core product, the MIST Ultrasound Healing Therapy® System delivers low frequency ultrasound through a saline mist. Unlike conventional wound treatments that are limited to treating the surface, MIST Therapy delivers ultrasound energy into and below the wound bed to stimulate cells to positively impact all critical aspects of the wound healing process. Celleration received 510K clearance from the FDA in 2005 with the full claim of “promote wound healing”. Shortly thereafter, the company introduced the MIST Therapy System to the US market and has since built an impressive body of clinical evidence demonstrating significant clinical and economic benefits in hundreds of facilities across the United States. Currently, over over 1 million MIST® Therapy treatments have been performed in the United States and U.K. benefiting more than 65,000 patients.
Developer of proprietary blood-based biomarker tests to transform the management of chronic respiratory diseases. The company is focused on addressing the unmet need for tools to provide a real-time, biological assessment of a patient’s disease state. ProterixBio's products will enable health care providers to better manage their patients and avoid unnecessary hospitalizations, leading to improved outcomes and reduced health care costs. It was founded in 2002 and headquartered in Billerica, Massachusetts.
Seahorse Bioscience provides analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. The company's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Seahorse Bioscience provides analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. The company's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers.
Achronix is a privately held fabless corporation based in Santa Clara, California. Achronix is the only company to offer high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Called Speedster®22i, Achronix’s FPGAs are built on Intel’s advanced 22nm process featuring 3-D Tri-Gate transistors and are the first FPGAs to include fully integrated hard IP protocol functions targeted for communications applications. Achronix also offers the Achronix CAD environment (ACE), an easy-to-use, mature, robust design-tool suite for our customers. ACE includes integrated support for industry-standard synthesis tools Synplify Pro and Precision Synthesis, from Synopsys and Mentor Graphics, respectively. Target markets for Achronix FPGAs include: Networking Optical/telecom High-performance computing Test and measurement Military and security Achronix Semiconductor Corporation was founded in 2004 with sales offices in the United States, Europe and China. It has research and development facilities in Santa Clara, California and Bangalore, India.
Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform. Celleration’s core product, the MIST Ultrasound Healing Therapy® System delivers low frequency ultrasound through a saline mist. Unlike conventional wound treatments that are limited to treating the surface, MIST Therapy delivers ultrasound energy into and below the wound bed to stimulate cells to positively impact all critical aspects of the wound healing process. Celleration received 510K clearance from the FDA in 2005 with the full claim of “promote wound healing”. Shortly thereafter, the company introduced the MIST Therapy System to the US market and has since built an impressive body of clinical evidence demonstrating significant clinical and economic benefits in hundreds of facilities across the United States. Currently, over over 1 million MIST® Therapy treatments have been performed in the United States and U.K. benefiting more than 65,000 patients.
TherOx operates as a private venture-financed medical device company based in Irvine, California. It is dedicated to elevating the standard of care for the treatment of heart attack patients. Its proprietary technology has been developed and iterated over a number of years and has been thoroughly studied in benchtop studies, animal studies, and clinical trials. Beyond the initial treatment of heart attack with SuperSaturated Oxygen Therapy (SSO2), TherOx has identified applications for SSO2 in stroke, oncology, and wound care. The Company currently holds 20 issued patents with additional applications pending.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease.
FlowCardia, Inc. is a medical device company founded in 2002 to design and develop a portfolio of innovative, catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. Chronic Total Occlusions (CTOs) are considered one of the last major clinical challenges in interventional therapy. The historic absence of safe and effective CTO recanalization devices is a major reason a large number of patients are still referred to coronary and peripheral bypass surgery and lower limb amputation.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.
Ception Therapeutics is a biopharmaceutical company focused on the discovery and development of novel products to address areas of unmet medical need. Ception was founded by experienced pharmaceutical executives in order to develop and commercialize therapeutics in areas of significant unmet medical need.
Achronix is a privately held fabless corporation based in Santa Clara, California. Achronix is the only company to offer high-density and high-performance application-targeted field programmable gate arrays (FPGAs). Called Speedster®22i, Achronix’s FPGAs are built on Intel’s advanced 22nm process featuring 3-D Tri-Gate transistors and are the first FPGAs to include fully integrated hard IP protocol functions targeted for communications applications. Achronix also offers the Achronix CAD environment (ACE), an easy-to-use, mature, robust design-tool suite for our customers. ACE includes integrated support for industry-standard synthesis tools Synplify Pro and Precision Synthesis, from Synopsys and Mentor Graphics, respectively. Target markets for Achronix FPGAs include: Networking Optical/telecom High-performance computing Test and measurement Military and security Achronix Semiconductor Corporation was founded in 2004 with sales offices in the United States, Europe and China. It has research and development facilities in Santa Clara, California and Bangalore, India.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
Ikonisys is transforming diagnostic medicine by enabling early, accurate and non-invasive disease detection. Through a unique combination of technology and science, Ikonisys is dedicated to helping physicians and researchers realize the promise of rare cell detection to give patients the best chance of managing their disease.
Light Sciences Oncology develops cancer and tumor treatment drugs. Additionally, it offers oncology drugs research and development services to treat hepatocellular carcinoma, metastatic colorectal cancer, and glioma. Light Sciences Oncology was founded in 1994 and is headquartered in Bellevue, Washington.
TherOx operates as a private venture-financed medical device company based in Irvine, California. It is dedicated to elevating the standard of care for the treatment of heart attack patients. Its proprietary technology has been developed and iterated over a number of years and has been thoroughly studied in benchtop studies, animal studies, and clinical trials. Beyond the initial treatment of heart attack with SuperSaturated Oxygen Therapy (SSO2), TherOx has identified applications for SSO2 in stroke, oncology, and wound care. The Company currently holds 20 issued patents with additional applications pending.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.